A correlação do câncer de mama triplo-negativo e o brca1

Abstract

This study aims to show the correlation of triple-negative breast cancer associated with mutations in the BRCA1 genes by means of a meta-analysis. Breast cancer is the most common cancer and the leading cause of cancer mortality in women worldwide. Triple negative breast cancer (TNBC) occurs in 15 to 20% of cases and is associated with rapid growth, early metastasis and worse prognosis than other breast cancer subtypes. Since sporadic triple negative tumors generally have the same histological characteristics and clinical outcome as BRCA1 mutation carriers, several studies have postulated that BRCA1 inactivation may also play a role in sporadic

TNBCs. A literature search was performed in PubMed, using the key-words “((triple- negative breast cancer) AND (BRCA1) AND (Associated) AND (expression))”. Of the

189 studies initially identified, 11 studies were included in this meta-analysis after applying the inclusion and exclusion criteria. Results shows a hight prevalence of BRCA1 mutations on triple negative breast cancer patients. Chemotherapy remains the basis of systemic treatment for breast cancer patients with the BRCA1 mutation. After treatment for triple-negative breast cancer, recurrence may occur, ie recurrence of the disease. Tumor recurrence and resistance to therapy remain a challenging problem in breast cancer.